Does Pseudohypoaldosteronism Mask the Diagnosis of Congenital Adrenal Hyperplasia? by Ağladıoğlu, Sebahat Yılmaz et al.
J Clin Res Pediatr En  docrinol 2011;3(4):219-221
DO  I: 10.4274/jcrpe.369
Sebahat Yılmaz Ağladıoğlu1, Zehra Aycan1, Havva Nur Peltek Kendirci1, Nilgün Erkek2, Veysel Nijat Baş1
1Dr. Sami Ulus Obstetrics and Gynecology, Pediatric Health and Disease Training and Research Hospital, Clinics of Pediatric Endocrinology, Ankara, Turkey
2Dr. Sami Ulus Obstetrics and Gynecology, Pediatric Health and Disease Training and Research Hospital, Clinics of Pediatrics, Ankara, Turkey
Ad dress  for  Cor res pon den ce
Sebahat Yılmaz Ağladıoğlu MD, Dr. Sami Ulus Obstetrics and Gynecology, Pediatric Health and Disease Training and Research Hospital, 
Clinics of Pediatric Endocrinology, Ankara, Turkey  Phone: +90 312 305 65 08 E-mail: sebahatyilmaz@yahoo.com
©Jo  ur  nal of Cli  ni  cal Re  se  arch in Pe  di  at  ric En  doc  ri  no  logy, Pub  lis  hed by Ga  le  nos Pub  lis  hing.
Does Pseudohypoaldosteronism Mask the Diagnosis
of Congenital Adrenal Hyperplasia?
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In tro duc ti on
Hyperpotassemia together with severe hyponatremia is
rare in infancy but important as it can be life-threatening.
Congenital adrenal hyperplasia (CAH) should be considered
first among adrenal diseases in the differential diagnosis of
hyponatremia if no gastrointestinal salt loss is present. Adrenal
hypoplasia, isolated aldosterone deficiency, drug effects and
pseudohypoaldosteronism (PHA) are other conditions that
should be kept in mind in the differential diagnosis (1).
A congenital renal anomaly can cause PHA due to a lack of
response to aldosterone in the distal tubule in male infants
under 3 months of age in the presence of obstructive 
uropathy, vesicoureteral reflux (VUR) and/or urinary tract 
infection (UTI) (2) and this can be confused with CAH. 
Compensated salt-losing CAH (SL-CAH) is accompanied
by increased androgen production, inadequate cortisol 
production and also increased renin and aldosterone levels;
serum electrolytes are normal in this condition (3). However,
hyponatremia and hyperpotassemia may develop due to the
lack of aldosterone effect in case of a  renal anomaly, VUR
and/or UTI (4) and this condition is called transient secondary
PHA. In such patients, PHA should be considered first if
hyponatremia and hyperpotassemia are present despite very
high levels of aldosterone. The serum aldosterone level is low
in the type of CAH with hyponatremia and hyperpotassemia as
there is no aldosterone synthesis.  
We present the cases of two patients who were seen at our
hospital with severe hyponatremia and hyperpotassemia. 
A diagnosis of PHA was first considered due to the high 
ABS TRACT
Hyponatremia and hyperpotassemia occurring in the first few weeks of
life primarily indicate aldosterone deficiency due to salt-losing 
congenital adrenal hyperplasia (SL-CAH), while mineralocorticoid 
deficiency and insensitivity are the main causes of hyponatremia and
hyperpotassemia in older infants. Some patients who present with 
vomiting and poor sucking, who have hyponatremia and 
hyperpotassemia and are initially diagnosed as CAH, during follow-up,
are found to suffer from pseudohypoaldosteronism (PHA). This situation
has been reported several times before. The cases described here 
represent the opposite situation: they presented with hyponatremia and
hyperpotassemia, thus PHA was considered as aldosterone levels were
very high, but subsequent investigation and genetic analysis led to the
diagnosis of SL-CAH.   
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aldosterone levels, but the ultimate diagnosis was CAH. These
cases are reported to emphasize the importance of not missing
CAH in patients presenting with a clinical picture of PHA.
Case Reports
Patient 1
A 45-day-old male baby born at term with a birth weight
of 2600 g presented with vomiting and poor sucking. Body
weight was 2600 g, indicating that the patient had not gained
weight since birth. Physical examination revealed severe
dehydration and mild scrotal hyperpigmentation. Laboratory
results were as follows: Serum Na: 114 mEq/L (N: 135-143
mEq/L),  K: 7.7 mEq/L (N: 3.5-5.5mEq/L), blood pH: 7.3,
HCO3: 12 mmol/L, BUN: 24 mg/dL (0-10 mg/dL), creatinine:
0.5 mg/dL (0.3-1.2 mg/dL). Urinalysis revealed leukocytes and
urine culture grew 100 000 colonies/mL E. coli. Intravenous
saline treatment was started together with antibiotics for the
UTI. Hormonal evaluation results were adrenocorticotropic
hormone (ACTH): 186 pg/mL (N: 3-46 pg/mL), basal cortisol:
8 µg/dL, renin: 836 pg/mL (N: 2.4-37 pg/mL) and aldosterone:
450 pg/mL (N: 20-700 pg/mL) - findings  which led to a 
preliminary diagnosis of PHA. A high ACTH value was noted.
The ACTH stimulation test performed to rule out CAH gave
the following results for 17-hydroxyprogesterone (17-OHP)
response: 27.7 ng/mL at 0 time, 37.2 ng/mL at 30 minutes and
35.3 ng/mL at 60 minutes. The patient was therefore 
diagnosed as CAH. Treatment was started with 
hydrocortisone and fludrocortisone and 1 g/day salt was
added to the diet. A high level of aldosterone despite salt 
loss is not expected in CAH. We therefore performed renal
ultrasonography to detect any renal anomaly that could cause
a lack of response to aldosterone and found grade 2
hydronephrosis of the left kidney and bilateral grade 4-5 VUR
on voiding cystogram. Amoxicillin prophylaxis was started.
Genetic analysis revealed a heterozygous Q318X and
homozygous IVS2 mutation of the 21-OH gene. Bilateral
Teflon injection was performed for the VUR. The patient is 
currently 4 years old, is on hydrocortisone and fludrocortisone
and is being followed-up without any problems.
Patient 2
A 35-day-old male baby born with a birth weight of 3500 g
at term presented to the emergency service of our hospital
with vomiting and failure to thrive. His weight was 3200 g, 
indicating a weight loss of 8% since birth. The patient's 
general condition was poor. Marked dehydration and mild
scrotal hyperpigmentation were present. Laboratory results
were as follows: Serum Na: 95 mEq/L (N: 135-143 mEq/L), 
K: 6.9 mEq/L (N: 3.5-5.5 mEq/L ), blood pH: 7.3, HCO3: 11.7
mmol/L, BUN: 26 mg/dL (0-10 mg/dL), creatinine: 0.47 mg/dL
(0.3-1.2 mg/dL). Urinalysis was positive for nitrite and 
leukocytes and there was a growth of 100 000 colonies of
Klebsiella on urine culture. Fludrocortisone and antibiotics
were started together with intravenous fluid treatment. Renal
ultrasonographic investigation for UTI showed prominent 
collective structures in the left kidney and grade 2 VUR on the
voiding cystogram. Antibiotic prophylaxis was started.
Hormonal evaluation revealed basal cortisol of 18 µg/dL,
ACTH 89.5 pg/mL (N: 3-46 pg/mL), renin: 186 pg/mL (N: 2.4-
37 pg/mL), and aldosterone level of 2 000 pg/mL (N:20-700
pg/mL). The preliminary diagnosis was PHA. The patient 
benefited from fludrocortisone treatment. Taking into account
the high serum ACTH level, an ACTH stimulation test was 
performed to rule out CAH and the 17-OHP response was as
follows: 27.6 ng/mL at 0 time, 44.1 ng/mL at 30 minutes and
41.2 ng/mL at 60 minutes. Hydrocortisone was added to the 
fludrocortisone and salt treatment. Genetic analysis revealed a
large deletion of the 21-OH gene. The patient is currently 1 year
old and is being followed-up without any problems on 
hydrocortisone, fludrocortisone and oral 1 g/day salt treatment. 
Age at presentation and laboratory findings of the patients
are given in Table 1.
Discussion
Aldosterone is the primary mineralocorticoid hormone
regulating serum electrolytes by enabling sodium absorption
and potassium secretion at the distal tubule. Hyponatremia,
hyperpotassemia, metabolic acidosis and hypovolemia 
develop due to renal salt loss in aldosterone deficiency.
Isolated aldosterone deficiency is rare but can be seen in
patients with the uncompensated salt-losing type of CAH and
also in patients with autoimmune adrenalitis and congenital
adrenal hypoplasia. PHA is a condition in which a high 
aldosterone level occurs together with signs and symptoms of
aldosterone deficiency. PHA can be primary or secondary.  
Secondary PHA is limited to the kidneys and can devel-
op due to drugs (cyclooxygenase inhibitors, angiotensin
Tab le  1. Laboratory findings of the patients
Age (days) Na/K ACTH Cortisol Basal Stimulated  PRA  Aldosterone  Gene
(mmol/L) (pg/mL) (µg/dL) 17-OHP 17-OHP  (pg/mL) (pg/mL) Mutation
(ng/mL) (ng/mL)
Case 1  45 114/7.7 186 8 27.6 37.2 836 450 Q318X
Case 2  35 95/6.9 89.5 18 28 44.1 186 2000 21-OH Large Deletion
ACTH: adrenocorticotropic hormone, 17-OHP: 17-hydroxyprogesterone, PRA: plasma renin activity221
converting enzyme inhibitors, potassium-sparing diuretics,
trimethoprim, cyclosporine, etc.), congenital renal malformations,
obstructive uropathy, VUR, UTI, tubulointerstitial nephritis,
nephropathy in sickle cell anemia, renal amyloidosis, and  in
multiple myeloma due to aldosterone insensitivity at the distal
renal tubule (4).
Secondary pseudohypoaldosteronism has been reported
in both sexes, but it can temporarily be seen due to congenital
renal anomaly, obstructive uropathy, VUR and/or UTI in male
infants under the age of 3 months, similar to our cases (2). A
lack of response of the renal tubule to aldosterone is present
in this condition. The mechanism of aldosterone resistance is
not fully understood, but it becomes exaggerated in the 
presence of UTI (4).
A review of the 68 temporary PHA cases reported
between 1983 and 2008 showed that 48 subjects had UTI
together with obstructive uropathy, VUR or other urinary 
system abnormality, while 8 cases had obstructive uropathy
or VUR without UTI. A UTI without obstruction was present
only in 5 of the 68 patients. These findings indicate that PHA
can develop in renal anomaly that does not cause obstruction,
obstructive uropathy, VUR and/or UTI. Also PHA can develop
even when there is only a UTI (5,6,7).
Melzi et al (8) found PHA in 17 of 50 infants (34%) aged 15
days to 15 months who had been  diagnosed as UTI. A urinary
system anomaly was found in all 17 of these patients and all
of these 17 patients had been diagnosed when they were
younger than 3 months (8). The symptoms usually resolve by
age 2 years with the completion of tubular maturation.  
Secondary transient PHA resembles the SL-CAH 
clinically and biochemically and there are cases in the 
literature who have been initially diagnosed as CAH and 
started on glucocorticoid and mineralocorticoid treatment
(4,9,10). The opposite situation applies to our cases and this
has not been reported or noted until now. The secondary PHA
in our cases was masking the CAH diagnosis. In the 
uncompensated salt-losing form of CAH, hyponatremia and
hyperpotassemia occur due to aldosterone deficiency.
Aldosterone is very high in the compensated salt-losing type
and serum Na and K levels are usually normal as a result of no
salt loss (3). The serum aldosterone levels were markedly high
in both our patients, but the salt loss first pointed towards a
diagnosis of PHA. However, the presence of VUR and UTI in the
patients had led to a lack of aldosterone efficacy and masked
the CAH diagnosis. Both our cases also had adequate basal
cortisol levels. The CAH diagnosis was confirmed with the
ACTH stimulation test and genetic analysis. 
In conclusion, the possibility of UTI and renal anomalies,
which are seen commonly in infancy and cause a lack of 
aldosterone effect, should be kept in mind and the patients
should be investigated accordingly. We suggest performing
appropriate investigations and genetic studies for the differential
diagnosis of CAH in the presence of renal problems or UTI in
cases  presenting with hyponatremia, hyperpotassemia and
high aldosterone levels. CAH should be ruled out in every case
suspected of having PHA, especially in the presence of 
problems that may cause aldosterone resistance. 
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